论文部分内容阅读
目的观察雷贝拉唑、埃索美拉唑与西咪替丁预防消化道出血的临床疗效。方法选取医院收治的消化道溃疡患者324例为研究对象,随机分为雷贝拉唑组、埃索美拉唑组、西咪替丁组,每组108例。比较3组患者出血率及不良反应发生率。结果雷贝拉唑组出血率为9.26%,埃索美拉唑组出血率为8.33%,均低于西咪替丁组的16.67%(P<0.05);雷贝拉唑组不良反应发生率为4.63%,埃索美拉唑组不良反应发生率为5.56%,均低于西咪替丁组的12.96%(P<0.05)。结论雷贝拉唑及埃索美拉唑可有效预防消化道出血,安全性较好,值得临床推广应用。
Objective To observe the clinical efficacy of rabeprazole, esomeprazole and cimetidine in the prevention of gastrointestinal bleeding. Methods A total of 324 patients with peptic ulcer admitted to hospital were enrolled in this study. They were randomly divided into rabeprazole group, esomeprazole group and cimetidine group, 108 cases in each group. The bleeding rate and the incidence of adverse reactions in 3 groups were compared. Results The hemorrhage rate in rabeprazole group was 9.26%, the bleeding rate in esomeprazole group was 8.33%, which was lower than that in cimetidine group (16.67%, P <0.05). The incidence of adverse reactions in rabeprazole group Was 4.63%. The incidence of adverse reactions in esomeprazole group was 5.56%, which was lower than that in cimetidine group (12.96%, P <0.05). Conclusion Rabeprazole and esomeprazole can effectively prevent gastrointestinal bleeding, which is safe and worthy of clinical application.